drugset / Trial / NCT04479865

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

NCT04479865

Phase 1 Unknown 49 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Timeline

Start
2020-07-28
Primary completion
2020-12-09
Completion
2021-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5207 Unknown 150 mg Other
Subject DA-5207 Unknown 170 mg Other
Subject Donepezil Small molecule 5 mg
Subject Donepezil Small molecule 10 mg

Indications

No indication recorded.